NCT01452139View on ClinicalTrials.gov

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions
STEMI
Interventions
GENETIC

Point-of-Care Genetic Testing

Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19\*2 \& ABCB1 3435 TT)

DRUG

Prasugrel

Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.

Trial Locations (1)

K1N 4W7

University of Ottawa Heart Institute, Ottawa

All Listed Sponsors
collaborator

Spartan Bioscience Inc.

INDUSTRY

lead

Ottawa Heart Institute Research Corporation

OTHER

NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) | Biotech Hunter | Biotech Hunter